Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (7764)	11/18/1998 8:54:00 PM
From: Robert K.	Respond to of 17367

Robert S.>your comment regarding meningo "Regardless of the "proof of concept" thesis, Wall Street does not get excited about therapeutic treatments that target small markets." My statement. >Ha. Delusional indeed. Ramones statement>beat on the brat with a baseball bat.

To: Robert S. who wrote (7764)	11/18/1998 9:16:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

I think Tex was on the mark also. We will see what happens if Neuprex is approved for Meningococcemia. Given the implications for its use in sepsis and that indeed the current trial is considered by many to be a proof of concept for sepsis, there is reason to think you are wrong. Ligands drug also is not designed to save lives. If you think people will not get enthused about a drug that saves more kids you are wrong about that too.

To: Robert S. who wrote (7764)	11/18/1998 10:32:00 PM
From: Tharos	Respond to of 17367

>>the history of share price projections posted on this board can best be described as delusional.<< I'll accept "best described as wishful," but looking over the total investment landscape and crowd valuations, delusional is hardly applicable, we just don't have the crowd dynamics...yet.